The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Pacific Smiles Group

Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover

Bullabulling Gold Project

Advising Minerals 260 on its purchase of the Bullabulling Gold Project from Norton Gold Fields (a wholly-owned subsidiary of one of the world’s largest gold producers, Zijin Mining Group)

Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)

Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)

Centogene GmbH

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases

Liontown Resources Limited

Advised Liontown Resources on its strategic partnership and convertible note funding with LG Energy Solution

Veen Bosch & Keuning

Advising Veen Bosch & Keuning, the largest book publisher in the Netherlands, on its sale to Simon & Schuster, one of the world’s preeminent publishing houses

Liontown Resources Limited

Advised Australian-based lithium company Liontown Resources Limited on its A$590m debt facility to fund the Kathleen Valley Lithium Project

myHomecare Group

Advising Australian Unity on its acquisition of myHomecare Group

Liontown Resources Limited

Advised Australian-based lithium company Liontown Resources Limited on its A$390m equity raising to fund the Kathleen Valley Lithium Project

Liontown Resources Limited

Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation

Clinigen Ltd’s portfolio of Established Medicines

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

Farmalider Group

Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH

Synfonium / Qwant / Shadow

Advised Banque des Territoires / Groupe Caisse des Dépôts (CDC), a French Public Institution, on the investment in the newly created platform Synfonium, incorporating Shadow, a cloud-based platform, and Qwant, a sovereign search engine. CDC will hold a 25% stake in Synfonium, while Octave Klaba and Miroslaw Klaba, the co-founders of OVHcloud, will hold the remaining 75%

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

Clinigen Ltd’s Lamda Laboratories

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Clinigen Ltd’s Proleukin

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

Kyowa Kirin International’s established medicines business

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

OZ Minerals Limited

Advising Australian-based copper company OZ Minerals Limited, on its response to two change of control proposals from BHP Group Limited, the world’s largest diversified resources company

brsk

Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager

Wildstone

Advising DigitalBridge, one of the largest global digital infrastructure investors, on the sale of Wildstone, Europe’s largest owner of independent outdoor media infrastructure, to Antin Infrastructure Partners

Liontown Resources

Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world-class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement and A$300m financing facility from Ford Motor Company

Netrics Digital Infrastructure

Advising NorthC, the largest regional data center provider in the Netherlands, on their agreement to acquire the data centers and connectivity services of Netrics in Switzerland

Syrah Resources

Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA

Netomnia

Advised Netomnia, a leading UK-based fiber operator, on its £295m fundraise led by DigitalBridge Investment Management with follow-on commitments from existing shareholders Soho Square Capital LLP and Advencap Limited